Posters

      High Content Screening (HCS) approach to characterize phenotypic changes occurring during long-term treatment of human bronchial epithelial cells with cigarette smoke total particulate matter

      Marescotti, D.; van der Toorn, M.; Laurent, A.; Luettich, K.; Frentzel, S.; Peitsch, M.; Hoeng, J.
      Conference date
      Sep 7, 2016
      Conference name
      Eurotox 2016
      Link to more information
      Link to more information
      Topic
      Summary

      No abstract available.

      Related Publications

      Systems Toxicology Assessment Of The Effect Of Repeated Cigarette Smoke Exposure On Human Respiratory Tract Tissue Cultures

      Systems Toxicology Aerosol Chemistry

      Comparison of the biological impact of cigarette smoke and a prototypic modified risk tobacco product on human versus rat primary normal bronchial epithelial cells

      Systems Toxicology Aerosol Chemistry

      Cilia of human MucilAir (TM) are less impacted by the exposure to the aerosol of a candidate modified risk tobacco product than to whole smoke from conventional cigarettes in vitro

      Systems Toxicology Aerosol Chemistry

      Application of a multi-layer systems toxicology framework for in vitro assessment of the biological effects of liquids and corresponding aerosols

      Systems Toxicology Aerosol Chemistry

      Cilia of human MucilAir (TM) are less impacted by the exposure to the aerosol of a candidate modified risk tobacco product than to whole smoke from conventional cigarettes in vitro

      Systems Toxicology Aerosol Chemistry

      Systems toxicology meta-analysis – From aerosol exposure to nanotoxicology

      Systems Toxicology Aerosol Chemistry

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.